According to this recent study, urine autofluorescence at 295 nm is significantly higher in patients with malignant melanoma at each clinical stage compared to the healthy group. Based on the results, it is assumed that the way malignant melanoma grows also affects urinary autofluorescence.
According to this recent study, proteomes of tumour‐derived small extracellular vesicles in patients’ plasma discriminate cancer from non‐cancer and identify proteins with potential to serve as prognostic biomarkers in melanoma.
According to this recent study, a better comprehension of the SPANX-A/D protein subfamily and its molecular mechanisms will help to describe new aspects of tumour cell biology and develop new therapeutic targets and tumour-directed pharmacological drugs for skin tumours.
This study aimed to evaluate whether baseline circulating tumour DNA (ctDNA) concentrations and kinetics could predict survival outcomes in melanoma patients. It concludes that retreatment and on-treatment BRAFV600-mutant ctDNA measurements could serve as independent, predictive biomarkers of clinical outcome with targeted therapy.
According to this recent study, LC3B can serve as a predictive biomarker of checkpoint inhibitor blockade to guide patient selection, as well as G9a inhibition as a strategy to extend the proportion of melanoma patients responding to immunotherapy.
This recent study identified several preoperative peripheral inflammatory markers as indicators for poor prognosis in melanoma patients with brain metastases undergoing neurosurgical treatment. Elevated initial C-reactive proteinvalues, higher neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio, and lower lymphocyte-to-monocyte ratio were associated with reduced overall survival.
Findings of this recent study provide a strong rationale for a randomized phase 3 study comparing neoadjuvant ipilimumab plus nivolumab versus standard adjuvant therapy with antibodies against the programmed cell death protein-1 (anti-PD-1) in macroscopic stage III melanoma.
The objective of this recent study was to define characteristics of lentiginous melanoma in situ (LM) and invasive lentiginous melanoma (LMM) in Australian patients managed at a tertiary centre and describe local recurrence or treatment failure rates after long‐term follow‐up. The study concludes that LM/LMM often recur late and are clinically subtle; therefore, careful monitoring and long‐term follow‐up are required.
This paper discusses the landscape of pembrolizumab safety and efficacy used in the adjuvant setting for high-risk, resected melanoma. This is placed in context with other available adjuvant therapies, and subgroup analyses are discussed.
According to this recent study, a combination of MAPK pathway inhibitors with endothelin-B receptor (ETBR) antagonists could have a synergistically beneficial effect in melanoma patients with hyperactivated MAPK signaling pathways.